WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007010398) CAVEOLIN-3 AND IN VITRO CULTURE OF HEPATITIS C VIRUS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/010398    International Application No.:    PCT/IB2006/002565
Publication Date: 25.01.2007 International Filing Date: 18.07.2006
IPC:
C12N 7/02 (2006.01), C12N 5/06 (2006.01), A01K 67/027 (2006.01), C12Q 1/70 (2006.01)
Applicants: NOVARTIS VACCINES AND DIAGNOSTICS SRL [IT/IT]; Via Fiorentina 1, I-53100 Siena (IT) (For All Designated States Except US).
MEROLA, Marcello [IT/IT]; (IT) (For US Only).
CROTTA, Stefania [IT/IT]; (IT) (For US Only).
BIANCHI, Alessia [IT/IT]; (IT) (For US Only)
Inventors: MEROLA, Marcello; (IT).
CROTTA, Stefania; (IT).
BIANCHI, Alessia; (IT)
Agent: MARSHALL, Cameron, John; Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA (GB)
Priority Data:
60/700,462 18.07.2005 US
Title (EN) CAVEOLIN-3 AND IN VITRO CULTURE OF HEPATITIS C VIRUS
(FR) CAVEOLINE-3 ET CULTURE IN VITRO DU VIRUS DE L'HEPATITE C
Abstract: front page image
(EN)Caveolin-3 has been identified as a cellular factor that associates with HCV protein El and E2, and is proposed as a cellular limiting factor. As an alternative possibility, caveolin-3 may act as a cellular receptor for HCV, acting alongside CD81. In either scenario, cells with increased expression of caveolin-3 will be better suited to the in vitro culture of HCV, and blocking the interaction between caveolin-3 and HCV proteins has therapeutic potential.
(FR)La cavéoline-3 a été identifiée comme étant un facteur cellulaire qui s'associe avec la protéine E1 et E2 du VHC et il a été proposé de l'utiliser en tant que facteur de limitation cellulaire. Selon une autre possibilité, la cavéoline-3 peut agir en tant que récepteur cellulaire pour le VHC, oeuvrant aux côtés de CD81. Dans les deux cas, l'expression accrue de la cavéoline-3 sera plus appropriée à la culture in vitro du VHC et le blocage de l'interaction entre la cavéoline-3 et les protéines VHC présente un potentiel thérapeutique.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)